Dictionary

allow_url_fopen is ENABLED Dictionary Search

achondroplasia

Synonyms

Noun

1. achondroplasty

2. osteosclerosis congenita, chondrodystrophy, genetic disease, genetic disorder, genetic abnormality, genetic defect, congenital disease, inherited disease, inherited disorder, hereditary disease, hereditary condition

Usage
Transcon CNP Shows Durable Benefits in Achondroplasia Study - The Clinical Trial Vanguard
RIBOMIC Files IND for Phase III Trial of Achondroplasia Drug in Japan - TipRanks
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
Oral infigratinib boosts growth velocity in achondroplasia study - 2 Minute Medicine
Ascendis Pharma (ASND) Is Down 5.8% After New Two-Year YUVIWEL Achondroplasia Data Release – Has The Bull Case Changed? - simplywall.st
Finding the right team for achondroplasia: Jeremy’s story - Boston Children's Hospital
Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling - Nature
Achondroplasia - The Lancet
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
Oral Infigratinib Therapy in Children with Achondroplasia - The New England Journal of Medicine
Ascendis Pharma (ASND) Shows Promising Results in Achondroplasia Treatment Study - GuruFocus
New Two-Year Data from Pivotal ApproaCH Trial Showing - GlobeNewswire
New treatment gives hope to children with achondroplasia - Loma Linda University
Abbisko Wins FDA Orphan Drug Status for Achondroplasia Candidate ABSK061 - TipRanks
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - simplywall.st
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug - BioSpace
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire
The latest on navepegritide for children with achondroplasia, with Carlos Bacino, MD - Contemporary Pediatrics
BioMarin stops mid-stage trials of bone disorder treatment - Reuters
Once-Weekly Treatment Approved for Achondroplasia in Kids - MedPage Today
New mouse model uncovers achondroplasia's cellular growth plate dysregulation - News-Medical
Weekly achondroplasia drug helps kids grow for 2 years in trial - Stock Titan
BioMarin halts Voxzogo trials due to safety signal - pharmaphorum
Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial - HCPLive
Once Weekly CNP Therapy Shows Promise In Advancing Achondroplasia Treatment - BioSpectrum Asia
Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial - HCPLive
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Oral medication boosts annualized height velocity for children with achondroplasia - Healio
Pregnancy and Delivery in a Woman With Achondroplasia: A Multidisciplinary Management Approach - Cureus
FDA pushes back decision on Ascendis' achondroplasia drug to February - FirstWord Pharma
Ascendis Pharma Reports Two-Year Data Showing Sustained Benefits of YUVIWEL in Children With Achondroplasia - TipRanks
BridgeBio drug for genetic cause of dwarfism succeeds in key study - statnews.com
Once-weekly agent boosts annualized growth velocity for children with achondroplasia - Healio
Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia - Contemporary Pediatrics
Oral infigratinib linked to improved growth and proportionality in achondroplasia - Contemporary Pediatrics
COACH Trial Confirms Durable Benefits in Achondroplasia - The Clinical Trial Vanguard
BioMarin discontinues dosing in certain Voxzogo trials after safety concern - Clinical Trials Arena
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward - BioSpace
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PR Newswire
Tyra Biosciences initiates paediatric study for achondroplasia treatment - Clinical Trials Arena
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com
Ascendis wins FDA approval for achondroplasia drug, waits on EU action - Endpoints News
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia - Contemporary Pediatrics
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 - Fierce Biotech
Drug Combo ‘Potentially Revolutionary’ for Achondroplasia - Medscape
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
TYRA: Phase II trials for dabogratinib target NMIBC, UTUC, and achondroplasia, with key data due this year - TradingView
BioMarin’s Voxzogo shows impact in pediatric achondroplasia - TipRanks
FDA approves Ascendis’ once-weekly achondroplasia treatment - Investing.com
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - MarketBeat
Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence - Cureus
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET - GlobeNewswire
Starting VOXZOGO in infancy boosts growth and body balance in achondroplasia - Stock Titan
Novel Combination Improved Growth in Kids With Achondroplasia, Study Suggests - MedPage Today
Management of achondroplasia in pregnancy - FIGO.org
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com South Africa
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - Sahm
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
Inside pharma’s race to deliver new treatments for dwarfism - Pharma Voice
Ascendis Pharma Receives FDA Approval for YUVIWEL®, First Once-Weekly Treatment for Achondroplasia in Children - Quiver Quantitative
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data - Investing.com
Results of Pivotal ApproaCH Trial of TransCon® CNP - GlobeNewswire
Ascendis reports strong results for achondroplasia combination therapy - Investing.com
Ascendis Announces Extension of FDA Review Period for - GlobeNewswire
Ribomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III - TipRanks
Arvada boy with dwarfism thrives at school thanks to doctor who goes the extra mile - KUSA.com
Camp Ellellbee Creates Space for Connection, Joy and Open Conversations About Skeletal Conditions - BioMarin Pharmaceutical
FDA accepts navepegritide application to treat children with achondroplasia - Contemporary Pediatrics
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com
Postoperative Rehabilitation Following Total Hip Arthroplasty in Achondroplasia: A Case Report Focused on Dislocation Prevention and Environmental Simulation - Cureus
Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential - simplywall.st
Ascendis reports interim analysis outcomes from achondroplasia trial - Clinical Trials Arena
Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia - TipRanks
Abbisko Therapeutics’ FGFR2/3 Inhibitor ABSK061 Granted FDA Orphan Drug Designation for Achondroplasia Treatment 12 - Minichart
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com India
Ribomic’s RBM-007 ready for phase III in achondroplasia - BioWorld MedTech
Ascendis scores FDA approval for weekly dwarfism drug - pharmaphorum
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia - MarketBeat
New investigational therapy shows promise for treating skeletal disorders - Drug Target Review
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
FDA approves once-weekly growth drug for children with achondroplasia - Stock Titan
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia - Contemporary Pediatrics
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech
'Door handle height at gym means we can't get in' - BBC
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Australia
Abbisko Wins FDA Rare Pediatric Disease Status for Achondroplasia Drug ABSK061 - TipRanks
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Yahoo Finance
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older - BioSpace
FDA delays decision on Ascendis' dwarfism prospect by 3 months - Fierce Biotech
Using Genetics to Improve Hypochondroplasia Diagnosis - BioMarin Pharmaceutical
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop - MedPage Today
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
Foreign Language Equivalents
Foreign Language Equivalents of 'achondroplasia'
Language Equivalent   Language Equivalent
French achondroplasie    Spanish
Misspellings - Typos
achondroplaasia,   avhondroplasia,   achondropkasia,   aachondroplasia,   achondriplasia,   achonsroplasia,   achondroplsia,   achondroplssia,   achodnroplasia,   achondroplaisa,   acohndroplasia,   achondropladia,   achondeoplasia,   achondroplasis,   achodroplasia,   achondroplasai,   achondroplaia,   achonddroplasia,   achonndroplasia,   achondro[lasia,   achoondroplasia,   ahcondroplasia,   achondrpplasia,   achondroplsaia,   achondrroplasia,   acjondroplasia,   achondroplasa,   achondoplasia,   acgondroplasia,   achonfroplasia,   achondroplasoa,   achondropasia,   achondroplasi,   achondrop;asia,   achondorplasia,   achondropalsia,   achondroplaaia,   achomdroplasia,   achondroplassia,   achondroplasiaa,   achondrplasia,   achondropllasia,   schondroplasia,   achondrooplasia,   achondrpolasia,   acchondroplasia,   achondtoplasia,   achondropplasia,   achpndroplasia,   achobdroplasia,   achondroplasiia,   achindroplasia,   axhondroplasia,   achondrolpasia,   achondrolasia,   achhondroplasia,   cahondroplasia,   chondroplasia,   acondroplasia,   achonroplasia,   ahondroplasia,   achondroplasua,   achnodroplasia,   achndroplasia,   achonrdoplasia,   achondroolasia
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z